Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2021-08-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
유상증자최종발행가액확정(일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the finalization of the issue price for a capital increase (paid-in capital increase/rights offering) by the company Abion. It specifies the number of shares, the final price per share, and the date of determination. This falls under the category of share issuance and capital changes.
2021-08-27 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) for the company Abion Inc. It details the finalization of the public offering price, the purpose of the funds, and the subscription procedures for the KOSDAQ listing. This is a formal regulatory filing related to share issuance and capital changes. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate classification for documents detailing new share issues and capital structure changes.
2021-08-27 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the offering price (공모가액 확정) for a new share issuance (IPO) by Abion Inc. (에이비온 주식회사). This type of document is a regulatory filing related to capital raising and share issuance, which falls under the 'Share Issue/Capital Change' category.
2021-08-27 Korean
[기재정정]투자설명서
Investor Presentation Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for an 'Investment Prospectus' (투자설명서) filed by Abion Inc. It details changes to the public offering price (from a range to a fixed price of 17,000 KRW) and related financial figures. In the context of Korean regulatory filings (DART), this is a formal amendment to a securities registration statement/prospectus. Among the provided categories, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of formal securities registration amendment, as it does not fit into specific categories like 10-K, ER, or IP.
2021-08-27 Korean
투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for Abion Inc., filed in South Korea. It contains detailed information regarding the company's business, risk factors, financial status, and the terms of a public offering (securities registration). In the context of financial filings, a prospectus is a formal document required by regulatory bodies (like the FSC/FSS in Korea) for public offerings, which falls under the category of Proxy Solicitation & Information Statement (PSI) or general regulatory filings. Given the specific nature of providing detailed investment information to potential shareholders for a public offering, 'PSI' is the most accurate classification.
2021-08-18 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for the company Abion Inc. It details amendments to the original filing, specifically regarding the public offering schedule, use of funds, and subscription procedures. This type of filing is a formal regulatory disclosure concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2021-08-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.